Gene · 8784
Papers4,557
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 4,557
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Zinc Transporters Serve as Prognostic Predictors and their Expression Correlates with Immune Cell Infiltration in Specific Cancer: A Pan-cancer Analysis. | J Cancer | 2024 | 38230214 | PubTator, text mining | PubMed |
| Targeting TIGIT for cancer immunotherapy: recent advances and future directions. | Biomark Res | 2024 | 38229100 | PubTator, text mining | PubMed |
| The Plasticity of Immune Cell Response Complicates Dissecting the Underlying Pathology of Multiple Sclerosis. | J Immunol Res | 2024 | 38213874 | PubTator, text mining | PubMed |
| Leveraging an immune cell signature to improve the survival and immunotherapy response of lung adenocarcinoma. | J Cancer | 2024 | 38213728 | PubTator, text mining | PubMed |
| Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2. | Nat Immunol | 2024 | 38212464 | PubTator, text mining | PubMed |
| Undersized telomeres in regulatory T cells link to the pathogenesis of allergic rhinitis. | iScience | 2024 | 38205251 | PubTator, text mining | PubMed |
| Comparative Evaluation of STEAP1 Targeting Chimeric Antigen Receptors with Different Costimulatory Domains and Spacers. | Int J Mol Sci | 2024 | 38203757 | PubTator, text mining | PubMed |
| Multiomics profiling reveals the benefits of gamma-delta (γδ) T lymphocytes for improving the tumor microenvironment, immunotherapy efficacy and prognosis in cervical cancer. | J Immunother Cancer | 2024 | 38199610 | PubTator, text mining | PubMed |
| Prediction and verification of the prognostic biomarker SLC2A2 and its association with immune infiltration in gastric cancer. | Oncol Lett | 2024 | 38192676 | PubTator, text mining | PubMed |
| Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma. | Cell Discov | 2024 | 38191529 | PubTator, text mining | PubMed |
| Comprehensive analysis reveals dual biological function roles of EpCAM in kidney renal clear cell carcinoma. | Heliyon | 2024 | 38187284 | PubTator, text mining | PubMed |
| Comprehensive analysis of a tryptophan metabolism-related model in the prognostic prediction and immune status for clear cell renal carcinoma. | Eur J Med Res | 2024 | 38183155 | PubTator, text mining | PubMed |
Modulation of mitochondrial activity by sugarcane (Saccharum officinarum L.) top extract and its bioactive polyphenols: a comprehensive transcriptomics analysis in C2C12 myotubes and HepG2 hepatocytes. | Nat Prod Bioprospect | 2024 | 38177614 | PubTator, text mining | PubMed |
| Identification and prognostic biomarkers among ZDHHC4/12/18/24, and APT2 in lung adenocarcinoma. | Sci Rep | 2024 | 38177255 | PubTator, text mining | PubMed |
| Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks. | Cell Death Dis | 2024 | 38177102 | PubTator, text mining | PubMed |
| Systematic analysis of the prognostic value and immunological function of LTBR in human cancer. | Aging (Albany NY) | 2024 | 38175686 | PubTator, text mining | PubMed |
| Generic design principles for antibody-based tumour necrosis factor (TNF) receptor 2 (TNFR2) agonists with FcγR-independent agonism. | Theranostics | 2024 | 38169605 | PubTator, text mining | PubMed |
| Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept. | J Exp Clin Cancer Res | 2024 | 38167055 | PubTator, text mining | PubMed |
| Agonist Antibodies for Cancer Immunotherapy: History, Hopes, and Challenges. | Clin Cancer Res | 2024 | 38153346 | PubTator, text mining | PubMed |
| Identification and validation of N7 -methylguanosine-associated gene NCBP1 as prognostic and immune-associated biomarkers in breast cancer patients. | J Cell Mol Med | 2024 | 38071502 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8784/papers?page=10